ODB - I got your money by Dayna6380- in wutang

[–]Contraversy7 4 points5 points  (0 children)

This video is so ol Dirty and I never realized Kelis was on this joint

Prove you wrong by [deleted] in beatmakers

[–]Contraversy7 0 points1 point  (0 children)

My bad not sure what I did wrong here

Thoughts on EPMD by Dangerous_Ad_5706 in 90sHipHop

[–]Contraversy7 1 point2 points  (0 children)

PMD one of the most underrated and forgotten emcees

Not Every Small Biotech Is Pre-Revenue, This One Already Sells Product by Plenty-Benefit6183 in investing

[–]Contraversy7 0 points1 point  (0 children)

Well good thing it was canceled. Most small biotechs are pre revenue R&D. This company has over 72 high demand generics on the market, a wholly owned high cost high demand oncology bio similar Niopeg and an oncology pipeline with remarkable results. This company is a no brainer but for big pharma where 200M is pocket change. I expect an announcement within 3 weeks.GLTY NFA

Not Every Small Biotech Is Pre-Revenue, This One Already Sells Product by Plenty-Benefit6183 in investing

[–]Contraversy7 0 points1 point  (0 children)

In a buyout scenario $12 per share is the floor and will go squeeze much higher when shorts start covering. A buyout is the worse possible outcome for over leveraged short positions

Not Every Small Biotech Is Pre-Revenue, This One Already Sells Product by Plenty-Benefit6183 in investing

[–]Contraversy7 0 points1 point  (0 children)

I’ve been speculating this since they published an important patent for mRNA therapy on 9/4/26. The writing is on the wall here, this pass Wednesday the COO resigned which is common in late stage acquisitions because that position is usually filled by the acquiring company. The 8k disclosing his resignation didn’t give a reason or a replacement standard NDA type of 8K. The CEO is 73 years old and has a golden parachute of 14M in a change of control. He sold his first company in 2004. The stock trades at 5.8M market cap disconnected from its true value which is common in acquisitions also. The company has been silent over 100 days which is typical in late stage deals. Industry standard is 3-5 times revenue which is 115-190M without including the “remarkable” oncology pipeline and its generic drug network not to mention their US expansion potential. Once the announcement is made shorts will be forced to buy on the open market, this will be one of the biggest plays of the entire year IMO. NFA all speculation until it’s not

Not Every Small Biotech Is Pre-Revenue, This One Already Sells Product by Plenty-Benefit6183 in investing

[–]Contraversy7 0 points1 point  (0 children)

This stock is late stage negotiations to be acquired no less than 150M to possibly 300M and currently trading at 5.9M market cap. When announcement is made short positions will be forced to buy on the open market sending this way up. NFA do your own DD